753 related articles for article (PubMed ID: 29898848)
1. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial.
Collet JP; Berti S; Cequier A; Van Belle E; Lefevre T; Leprince P; Neumann FJ; Vicaut E; Montalescot G
Am Heart J; 2018 Jun; 200():44-50. PubMed ID: 29898848
[TBL] [Abstract][Full Text] [Related]
2. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Windecker S; Tijssen J; Giustino G; Guimarães AH; Mehran R; Valgimigli M; Vranckx P; Welsh RC; Baber U; van Es GA; Wildgoose P; Volkl AA; Zazula A; Thomitzek K; Hemmrich M; Dangas GD
Am Heart J; 2017 Feb; 184():81-87. PubMed ID: 27892890
[TBL] [Abstract][Full Text] [Related]
3. Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy.
Montalescot G; Redheuil A; Vincent F; Desch S; De Benedictis M; Eltchaninoff H; Trenk D; Serfaty JM; Charpentier E; Bouazizi K; Prigent M; Guedeney P; Salloum T; Berti S; Cequier A; Lefèvre T; Leprince P; Silvain J; Van Belle E; Neumann FJ; Portal JJ; Vicaut E; Collet JP;
JACC Cardiovasc Interv; 2022 Sep; 15(18):1794-1804. PubMed ID: 36137682
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
Van Mieghem NM; Unverdorben M; Valgimigli M; Mehran R; Boersma E; Baber U; Hengstenberg C; Shi M; Chen C; Saito S; Veltkamp R; Vranckx P; Dangas GD
Am Heart J; 2018 Nov; 205():63-69. PubMed ID: 30172099
[TBL] [Abstract][Full Text] [Related]
5. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial.
Rodés-Cabau J; Masson JB; Welsh RC; Garcia Del Blanco B; Pelletier M; Webb JG; Al-Qoofi F; Généreux P; Maluenda G; Thoenes M; Paradis JM; Chamandi C; Serra V; Dumont E; Côté M
JACC Cardiovasc Interv; 2017 Jul; 10(13):1357-1365. PubMed ID: 28527771
[TBL] [Abstract][Full Text] [Related]
6. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement.
Abdul-Jawad Altisent O; Durand E; Muñoz-García AJ; Nombela-Franco L; Cheema A; Kefer J; Gutierrez E; Benítez LM; Amat-Santos IJ; Serra V; Eltchaninoff H; Alnasser SM; Elízaga J; Dager A; García Del Blanco B; Ortas-Nadal Mdel R; Marsal JR; Campelo-Parada F; Regueiro A; Del Trigo M; Dumont E; Puri R; Rodés-Cabau J
JACC Cardiovasc Interv; 2016 Aug; 9(16):1706-17. PubMed ID: 27539691
[TBL] [Abstract][Full Text] [Related]
7. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.
Collet JP; Van Belle E; Thiele H; Berti S; Lhermusier T; Manigold T; Neumann FJ; Gilard M; Attias D; Beygui F; Cequier A; Alfonso F; Aubry P; Baronnet F; Ederhy S; Kasty ME; Kerneis M; Barthelemy O; Lefèvre T; Leprince P; Redheuil A; Henry P; Portal JJ; Vicaut E; Montalescot G;
Eur Heart J; 2022 Aug; 43(29):2783-2797. PubMed ID: 35583186
[TBL] [Abstract][Full Text] [Related]
8. Comparison of apixaban versus aspirin for the prevention of latent bioprosthetic aortic valve thrombosis: study protocol for a prospective randomized trial.
Kopjar T; Gasparovic H; Paar MH; Lovric D; Cerina P; Tokic T; Milicic D
Trials; 2024 May; 25(1):324. PubMed ID: 38755709
[TBL] [Abstract][Full Text] [Related]
9. Direct Oral Anticoagulant Use After Transcatheter Aortic Valve Replacement: A Case Series.
Hendricks AK; Nei SD; Greason KL; Scott RA
J Cardiovasc Pharmacol; 2020 Jan; 75(1):41-44. PubMed ID: 31633585
[TBL] [Abstract][Full Text] [Related]
10. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
De Backer O; Dangas GD; Jilaihawi H; Leipsic JA; Terkelsen CJ; Makkar R; Kini AS; Veien KT; Abdel-Wahab M; Kim WK; Balan P; Van Mieghem N; Mathiassen ON; Jeger RV; Arnold M; Mehran R; Guimarães AHC; Nørgaard BL; Kofoed KF; Blanke P; Windecker S; Søndergaard L;
N Engl J Med; 2020 Jan; 382(2):130-139. PubMed ID: 31733182
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial.
Park DW; Ahn JM; Kang DY; Kim KW; Koo HJ; Yang DH; Jung SC; Kim B; Wong YTA; Lam CCS; Yin WH; Wei J; Lee YT; Kao HL; Lin MS; Ko TY; Kim WJ; Kang SH; Yun SC; Lee SA; Ko E; Park H; Kim DH; Kang JW; Lee JH; Park SJ;
Circulation; 2022 Aug; 146(6):466-479. PubMed ID: 35373583
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: A retrospective single-center registry analysis.
Holy EW; Kebernik J; Allali A; El-Mawardy M; Richardt G; Abdel-Wahab M
Cardiol J; 2017; 24(6):649-659. PubMed ID: 28497845
[TBL] [Abstract][Full Text] [Related]
13. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Connors JM; Brooks MM; Sciurba FC; Krishnan JA; Bledsoe JR; Kindzelski A; Baucom AL; Kirwan BA; Eng H; Martin D; Zaharris E; Everett B; Castro L; Shapiro NL; Lin JY; Hou PC; Pepine CJ; Handberg E; Haight DO; Wilson JW; Majercik S; Fu Z; Zhong Y; Venugopal V; Beach S; Wisniewski S; Ridker PM;
JAMA; 2021 Nov; 326(17):1703-1712. PubMed ID: 34633405
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
[TBL] [Abstract][Full Text] [Related]
15. Antithrombotic Therapy After TAVR.
Geisler T; Droppa M; Muller K; Borst O
Curr Vasc Pharmacol; 2018; 16(5):437-445. PubMed ID: 29345593
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Hoshi T; Sato A; Nogami A; Gosho M; Aonuma K;
J Cardiol; 2017 Apr; 69(4):648-651. PubMed ID: 27443596
[TBL] [Abstract][Full Text] [Related]
17. Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement.
Seeger J; Gonska B; Rodewald C; Rottbauer W; Wöhrle J
JACC Cardiovasc Interv; 2017 Jan; 10(1):66-74. PubMed ID: 27916486
[TBL] [Abstract][Full Text] [Related]
18. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
Dangas GD; Tijssen JGP; Wöhrle J; Søndergaard L; Gilard M; Möllmann H; Makkar RR; Herrmann HC; Giustino G; Baldus S; De Backer O; Guimarães AHC; Gullestad L; Kini A; von Lewinski D; Mack M; Moreno R; Schäfer U; Seeger J; Tchétché D; Thomitzek K; Valgimigli M; Vranckx P; Welsh RC; Wildgoose P; Volkl AA; Zazula A; van Amsterdam RGM; Mehran R; Windecker S;
N Engl J Med; 2020 Jan; 382(2):120-129. PubMed ID: 31733180
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation.
Nijenhuis VJ; Brouwer J; Søndergaard L; Collet JP; Grove EL; Ten Berg JM
Heart; 2019 May; 105(10):742-748. PubMed ID: 30867148
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet strategy after transcatheter aortic valve replacement: an updated meta-analysis.
Ma X; Xu Z; Li J; Zhao D; Kong X; Ma J; Ma H; Yun Y; Sun L; Zhang Y; Wei D; Jiao Q; Zou C; Wang Z
J Cardiovasc Surg (Torino); 2019 Oct; 60(5):624-632. PubMed ID: 31486613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
